The pharmaceutical industry warns of the risk of Europe becoming a non-driving, receiving market for innovation

The European employer of the innovative industry has its sights set on the roadmap of the Industrial Strategy for the sector, which will be published next week. The director general of Efpia believes that Europe may have the last chance to relaunch the continent in the world race for biomedical innovation. The EU has lost […]

The pharmaceutical sector, the basis of a new production model in Spain

Source: www.expansion.com The pharmaceutical industry is positioned as a leading actor for the necessary evolution of the Spanish economy towards a productive model supported by innovation and research. During his time as acting president, Pedro Sánchez stressed that the objective of the Government would be “to strengthen economic growth on much more productive bases, such […]

Create the test that predicts the risk of infection in kidney transplants

Source: www.immedicohospitalario.es The clinical efficacy of this new diagnosed tool has been tested in five hospitals with clinical trials, which is a step towards personalized medicine in the field of transplants. The Renal Transplant Unit of the Nephrology Service of Bellvitge University Hospital has developed and demonstrated the efficacy of a new immunological test to […]

Drug R&D: increasingly high development costs and lower returns

The expected return on investment in new medicines stands at 1.8%, the lowest point in the last 10 years, according to a Deloitte report On the contrary, the development costs of a new molecule have increased by 67% in this same period, says the study The greater specificity of the medications, which are aimed at […]

SEFH joins the World Cancer Day recalling the importance of healthy habits and research

Source: www.immedicohospitalario.es The arrival of advanced therapies, such as CAR-T cells, immunotherapy or other targeted treatments and their incorporation into the assistance protocols are being able to modify the course of many oncological and hematological pathologies and pose a new challenge for oncological pharmacists, which must be maintained continuously updated. The Spanish Society of Hospital […]

Clinical research in Spain seeks new impulses to maintain its leadership position in Europe

Farmaindustria advocates strengthening the role of the Spanish Agency for Medicines and Health Products (Aemps) to maintain the competitiveness of our country in biomedical R&D The pharmaceutical industry has redoubled its research efforts in infrequent and pediatric diseases, as revealed in the jornada Future of Clinical Research in Spain ’conference, held today in Madrid Source: […]

The pharmaceutical industry responds to the increased incidence of cancer: one in two clinical trials focuses on oncology

The impulse to biomedical research in this area allows disease control for longer, increases survival and improves the quality of life of patients The Spanish Agency for Medicines and Health Products has closed 2019 with 309 authorizations for clinical trials for cancer, and the pharmaceutical industry has more than 1,800 new medicines in the world. […]

Clinical trials, cost savings for the system and innovative therapies for the patient

They are essential to demonstrate the safety of medicines, but they also represent a significant cost savings in the health centers where they are carried out. Source: www.elespanol.com Clinical trials are essential for the incorporation of new medicines into the health system, but they also grant other benefits that, if less obvious, could be overlooked. […]

The Economic and Social Council advises the Government to promote investment in R&D

Source: www.actasanitaria.es Farmaindustria has reported that the Economic and Social Council (CES), a consultative body of the Government in socio-economic and labor matters, published a comprehensive analysis of the industrial sector in Spain, in which it issues a series of recommendations for public administrations to make a determined commitment to a productive model based on […]

2019, a new year of “progress” and “remarkable progress” for pharmaceutical innovation

The European agency EMA gives green light to 30 new drugs and the US FDA, to 48 Hematology and oncology account for more than a third of the new approvals, and almost one in four are therapies for rare diseases Source: www. farmaindustria.es The European Medicines Agency (EMA) has released on Thursday its annual report […]